The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

The drug, called Enhertu, can give patients with a specific type of incurable breast cancer an extra six months to live on ...

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's National Medical Products Administration ...

Mauro Vitali, head of Oncology Business Division of Daiichi Sankyo Italia Photos: Courtesy of Daiichi Sankyo. As one of the ...

“Our vision is that every Black individual diagnosed with breast cancer will feel the support of a loving community, and will ...

Drugmaker Daiichi Sankyo is working to boost production of its newer-generation cancer therapies that target diseased cells, across Japan, Europe and the US.

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY – Get Free Report) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totalling 3, ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Hiroyuki Okuzawa, President and COO at Daiichi Sankyo, says the company is working to boost production of its ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...